Ulrike Protzer 

  •                                 
    Extbase Variable Dump
    'distribution:BiomSpeaker.html' (29 chars)
    
                            
  •                                     
    Extbase Variable Dump
    'fileadmin/Webdata/Uploads/Veranstaltungen/2025/BayOConnect_2025/Speaker/Prot
     zer_300x300.jpg    ' (91 chars)
    
                                
  •                                     
    Extbase Variable Dump
    'Ulrike Protzer' (14 chars)
    
                                
  •                                     
    Extbase Variable Dump
    'Director of the Institutes of Virology, Helmholtz Munich & Technical Univers
     ity of Munich    ' (89 chars)
    
                                
  •                                     
    Extbase Variable Dump
    'Ulrike Protzer is an expert virologist with many years of research in molecu
     lar virology, virus-host interaction, and immunology. Ulrike studied medicin
     e in Germany, South Africa, and Switzerland. She has a strong background in 
     infectious diseases, hepatology, and medical virology, which she obtained du
     ring her clinical training. She has passed Internal Medicine, Microbiology, 
     and Virology board exams.<br> Since the end of 2007, Ulrike Protzer has been
      director of the Institutes of Virology at Helmholtz Munich and the Technica
     l University of Munich (TUM) and holds the Chair of Virology. Focusing on pr
     omoting young scientists, she serves as vice dean of the School of Medicine.
     <br> 2011-2018, she was a member of the founding executive board of the Germ
     an Center for Infection Research. Currently, she leads several national and 
     international research consortia and serves on numerous advisory and supervi
     sory boards.<br> Her scientific efforts focus on understanding the interacti
     on between viruses and their human hosts and translating this knowledge into
      novel (immune)therapeutic approaches. For many years, she has focused on th
     e hepatitis B virus that kills more than 820,000 humans yearly. Her group ex
     ploits vaccines and T-cell therapies to reconstitute HBV-specific immunity w
     ith the clear goal to finally cure HBV. Since the start of the pandemic, she
      has also studied the immune response protecting from COVID-19 and performed
      clinical studies on the effect of vaccines on COVID-19 control.<br> <br> "T
     he disruptive power of the COVID-19 pandemics showed that infectious disease
      research is more important than ever. To be better prepared, it is of utmos
     t importance to understand pathogens and particularly viruses with pandemic 
     potential and how we can rapidly diagnose and combat them. An important focu
     s besides broadly active antivirals and vaccines is understanding the virus 
     pathology as newly emerging viruses of concern share the feature of causing 
     similar pathology due to...    ' (2176 chars)